Shandong Boan Biotechnology Co. Ltd. Receives FDA Approval to Initiate Clinical Trials for BA1302 in the U.S

Reuters

2025/06/17

Shandong Boan Biotechnology Co. Ltd. Receives FDA Approval to Initiate Clinical Trials for BA1302 in the U.S

Shandong Boan Biotechnology Co. Ltd. has announced that it has received approval from the U.S. Food and Drug Administration (FDA) to initiate clinical trials for its novel antibody-drug conjugate $(ADC)$, BA1302, targeting CD228 for the treatment of various solid tumors. BA1302 has previously been granted Orphan Drug Designations by the FDA for squamous non-small cell lung cancer and pancreatic cancer. Currently, a Phase 1 clinical trial is ongoing in China, with development progress leading similar projects globally. The company is committed to accelerating the clinical development of BA1302 worldwide, aiming to explore its potential as a monotherapy and in combination with other treatments, thereby offering new hope for targeted cancer treatment. This announcement marks a significant step forward in Shandong Boan Biotechnology's efforts to provide innovative cancer therapies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief on June 17, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2544090939"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544090939\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2544090939?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-17 12:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544090939","market":"fut","top_or_hot":-1,"title":"Shandong Boan Biotechnology Co. Ltd. Receives FDA Approval to Initiate Clinical Trials for BA1302 in the U.S","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Shandong Boan Biotechnology Co. Ltd. Receives FDA Approval to Initiate Clinical Trials for BA1302 in the U.S\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Shandong Boan Biotechnology Co. Ltd. has announced that it has received approval from the U.S. Food and Drug Administration (FDA) to initiate clinical trials for its novel antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, BA1302, targeting CD228 for the treatment of various solid tumors. BA1302 has previously been granted Orphan Drug Designations by the FDA for squamous non-small cell lung cancer and pancreatic cancer. Currently, a Phase 1 clinical trial is ongoing in China, with development progress leading similar projects globally. The company is committed to accelerating the clinical development of BA1302 worldwide, aiming to explore its potential as a monotherapy and in combination with other treatments, thereby offering new hope for targeted cancer treatment. This announcement marks a significant step forward in Shandong Boan Biotechnology's efforts to provide innovative cancer therapies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief on June 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shandong Boan Biotechnology Co. Ltd. Receives FDA Approval to Initiate Clinical Trials for BA1302 in the U.S</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShandong Boan Biotechnology Co. Ltd. Receives FDA Approval to Initiate Clinical Trials for BA1302 in the U.S\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-17 12:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Shandong Boan Biotechnology Co. Ltd. Receives FDA Approval to Initiate Clinical Trials for BA1302 in the U.S\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Shandong Boan Biotechnology Co. Ltd. has announced that it has received approval from the U.S. Food and Drug Administration (FDA) to initiate clinical trials for its novel antibody-drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a>, BA1302, targeting CD228 for the treatment of various solid tumors. BA1302 has previously been granted Orphan Drug Designations by the FDA for squamous non-small cell lung cancer and pancreatic cancer. Currently, a Phase 1 clinical trial is ongoing in China, with development progress leading similar projects globally. The company is committed to accelerating the clinical development of BA1302 worldwide, aiming to explore its potential as a monotherapy and in combination with other treatments, thereby offering new hope for targeted cancer treatment. This announcement marks a significant step forward in Shandong Boan Biotechnology's efforts to provide innovative cancer therapies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief on June 17, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1583","symbol_name":"高瓴概念","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250617:nNDL9pqK1f:1","article_id":"2544090939","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544090939","pubTimestamp":1750133187,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Shandong Boan Biotechnology Co. Ltd. has announced that it has received approval from the U.S. Food and Drug Administration  to initiate clinical trials for its novel antibody-drug conjugate , BA1302, targeting CD228 for the treatment of various solid tumors. BA1302 has previously been granted Orphan Drug Designations by the FDA for squamous non-small cell lung cancer and pancreatic cancer. Currently, a Phase 1 clinical trial is ongoing in China, with development progress leading similar projects globally. The company is committed to accelerating the clinical development of BA1302 worldwide, aiming to explore its potential as a monotherapy and in combination with other treatments, thereby offering new hope for targeted cancer treatment. This announcement marks a significant step forward in Shandong Boan Biotechnology's efforts to provide innovative cancer therapies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT striv","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1583":"高瓴概念","BK1161":"生物科技","BK1606":"中医药概念","BK1191":"制药","02186":"绿叶制药","06955":"博安生物"},"translate_title":"山东博安生物科技有限公司获得FDA批准在美国启动BA1302临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02186":0.9,"06955":0.9},"content_text":"Shandong Boan Biotechnology Co. Ltd. Receives FDA Approval to Initiate Clinical Trials for BA1302 in the U.S\n    \n\n        Shandong Boan Biotechnology Co. Ltd. has announced that it has received approval from the U.S. Food and Drug Administration (FDA) to initiate clinical trials for its novel antibody-drug conjugate $(ADC)$, BA1302, targeting CD228 for the treatment of various solid tumors. BA1302 has previously been granted Orphan Drug Designations by the FDA for squamous non-small cell lung cancer and pancreatic cancer. Currently, a Phase 1 clinical trial is ongoing in China, with development progress leading similar projects globally. The company is committed to accelerating the clinical development of BA1302 worldwide, aiming to explore its potential as a monotherapy and in combination with other treatments, thereby offering new hope for targeted cancer treatment. This announcement marks a significant step forward in Shandong Boan Biotechnology's efforts to provide innovative cancer therapies.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shandong Boan Biotechnology Co. Ltd. published the original content used to generate this news brief on June 17, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}